Human N-terminal pro brain natriuretic peptide CLIA Kit


​​​​​​​Human N-terminal pro brain natriuretic peptide CLIA Kit is a Chemiluminescence Immunoassay (CLIA) intended for the quantitative measurement of human N-terminal pro brain natriuretic peptide concentration in serum.

For in-vitro diagnostics purposes only


The Human N-terminal pro brain natriuretic peptide CLIA Kit is designed, developed, and produced for the quantitative measurement of human NT-PROBNP level in serum samples. The assay utilizes a two-site “sandwich” technique with two antibodies that bind to different epitopes of NT-PROBNP.
Assay calibrators, controls, or patient serum samples are added directly to a reaction vessel together with streptavidin coated magnetic particles and biotinylated anti-NT-PROBNP polyclonal antibody. The magnetic particles capture the biotin antibody as well as an immuno complex in the form of “magnetic particles–biotin NT-PROBNP antibody–NT-PROBNP–acridinium ester NT-PROBNP antibody”. Materials bound to the solid beads are held in a magnetic field while unbound materials are washed away. Then, trigger solutions are added to the reaction vessel and light emission is measured with the ECL100 analyzer. The relative light units (RLU) are proportional to the concentration of a NT-PROBNP in the sample. The amount of analyte in the sample is determined from a stored, multi-point calibration curve and reported in serum NT-PROBNP concentration.


Catalog no. SKT-031
Target Human N-terminal pro brain natriuretic peptide
Species Human
Method Sandwich CLIA
Tests Per Kit 100 tests
Detection Flash AE Chemiluminescence
Sensitivity / LLOD 10.0 pg/mL.
Dynamic Range 10.0 pg/mL to 35000.0 pg/mL
Total Incubation Time
Sample Type Serum
Sample Volume 20 µL
Storage Temperature 2-8 °C

Selected Literature

​​​​​​​1. De Lemos JA, McGuire DK, Drazner MH. B-type natriuretic peptide in cardiovascular disease. Lancet2003; 362:316-22.
2. Pfister R, Scholz M, Wielckens K, Erdmann E, Schneider CA. The value of natriuretic peptidesNT-pro-BNP and BNP for the assessment of left-ventricular volume and function. A prospective study of 150patients. Deutsche medizinische Wochenschrift (1946) 2002; 127(49):2605.
3. Nousiainen T, Vanninen E, Jantunen E, Puustinen J, Remes J, Rantala A, et al. Natriuretic peptides duringthe development of doxorubicin-induced left ventricular diastolic dysfunction. Journal of internal medicine2002; 251(3):228.

For in-vitro diagnostic use.